Wei-Ming Chen1,2,3, Cheng-Shyong Wu1,2, Jing-Lan Liu3,4, Chia-Ming Yeh5, Libby Tseng5, Hao-Chun Huang1, Pey-Jium Chang3, Shu-Fen Wu6. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan. 2. College of Medicine, Chang Gung University, Taoyuan, Taiwan. 3. Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 4. Department of Pathology, Chang Gung Memorial Hospital, Chiayi, Taiwan. 5. Department of Life Science and Institute of Molecular Biology, National Chung Cheng University, No.168, University Rd., Min-Hsiung, Chia-Yi, 62247, Taiwan, Republic of China. 6. Department of Life Science and Institute of Molecular Biology, National Chung Cheng University, No.168, University Rd., Min-Hsiung, Chia-Yi, 62247, Taiwan, Republic of China. biosfw@ccu.edu.tw.
Abstract
PURPOSE: Helios belongs to Ikaros family, which plays an important role in the cell-fate decision and control cell proliferation; abnormal expressions in leukemia are associated with poor prognosis. In this study, we investigated the Helios expression between Helicobacter pylori infection and prognosis in gastric cancer patients. METHODS: A total of 67 gastric cancer patients who received partial or full gastrectomies were enrolled. Helios expression by immunohistochemistry and mRNA was investigated with the clinical stage, Helicobacter pylori infection, CD4 expression, FoxP3 expression and prognosis. RESULTS: From the immunohistochemistry stain, we found that the Helios was expressed in both cancer cell and tumor-infiltrated lymphocytes. The high expression of Helios in gastric tumor cells had a better median overall survival rate in gastric cancer patients (50.7 ± 3.2 vs. 34.1 ± 4.9 months; P = 0.015), Helicobacter pylori-infected patients (51.1 ± 3.5 vs. 30.4 ± 5.1 months; P = 0.007) and advanced gastric cancer patients (42.1 ± 5.5 vs. 23.2 ± 4.8 months; P = 0.043). From multivariate analysis, the Helios expression in gastric tumor cells was an independent factor to predict better survival in all gastric cancers (HR = 2.78; 95 % confidence interval [CI], 1.09-7.09; P = 0.032) and advanced gastric cancer patients (HR = 2.85; 95 % confidence interval [CI], 1.00-8.13; P = 0.03). CONCLUSIONS: Higher expression of Helios in gastric tumor cells predicts better survival in gastric cancer patients, especially for Helicobacter pylori-infected and advanced-stage gastric cancer patients.
PURPOSE:Helios belongs to Ikaros family, which plays an important role in the cell-fate decision and control cell proliferation; abnormal expressions in leukemia are associated with poor prognosis. In this study, we investigated the Helios expression between Helicobacter pyloriinfection and prognosis in gastric cancerpatients. METHODS: A total of 67 gastric cancerpatients who received partial or full gastrectomies were enrolled. Helios expression by immunohistochemistry and mRNA was investigated with the clinical stage, Helicobacter pyloriinfection, CD4 expression, FoxP3 expression and prognosis. RESULTS: From the immunohistochemistry stain, we found that the Helios was expressed in both cancer cell and tumor-infiltrated lymphocytes. The high expression of Helios in gastric tumor cells had a better median overall survival rate in gastric cancerpatients (50.7 ± 3.2 vs. 34.1 ± 4.9 months; P = 0.015), Helicobacter pylori-infected patients (51.1 ± 3.5 vs. 30.4 ± 5.1 months; P = 0.007) and advanced gastric cancerpatients (42.1 ± 5.5 vs. 23.2 ± 4.8 months; P = 0.043). From multivariate analysis, the Helios expression in gastric tumor cells was an independent factor to predict better survival in all gastric cancers (HR = 2.78; 95 % confidence interval [CI], 1.09-7.09; P = 0.032) and advanced gastric cancerpatients (HR = 2.85; 95 % confidence interval [CI], 1.00-8.13; P = 0.03). CONCLUSIONS: Higher expression of Helios in gastric tumor cells predicts better survival in gastric cancerpatients, especially for Helicobacter pylori-infected and advanced-stage gastric cancerpatients.
Authors: Raquel Martín-Ibáñez; Empar Crespo; Miriam Esgleas; Noelia Urban; Bei Wang; Ronald Waclaw; Katia Georgopoulos; Salvador Martínez; Kenneth Campbell; Carlos Vicario-Abejón; Jordi Alberch; Susan Chan; Philippe Kastner; John L Rubenstein; Josep M Canals Journal: Stem Cells Dev Date: 2012-01-26 Impact factor: 3.272
Authors: Kyung-Ju Kim; Kyu Sang Lee; Hwa Jin Cho; Young Hoon Kim; Han Kwang Yang; Woo Ho Kim; Gyeong Hoon Kang Journal: Hum Pathol Date: 2013-12-12 Impact factor: 3.466
Authors: K Hahm; B S Cobb; A S McCarty; K E Brown; C A Klug; R Lee; K Akashi; I L Weissman; A G Fisher; S T Smale Journal: Genes Dev Date: 1998-03-15 Impact factor: 11.361
Authors: Derese Getnet; Joseph F Grosso; Monica V Goldberg; Timothy J Harris; Hung-Rong Yen; Tullia C Bruno; Nicholas M Durham; Edward L Hipkiss; Kristin J Pyle; Satoshi Wada; Fan Pan; Drew M Pardoll; Charles G Drake Journal: Mol Immunol Date: 2010-03-11 Impact factor: 4.407
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396